{"id":"after-cpb-tranexamic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Thromboembolic events (deep vein thrombosis, pulmonary embolism)"},{"rate":null,"effect":"Seizures"},{"rate":null,"effect":"Renal dysfunction"},{"rate":null,"effect":"Visual disturbances"}]},"_chembl":{"chemblId":"CHEMBL877","moleculeType":"Small molecule","molecularWeight":"157.21"},"_fixedAt":"2026-03-30T16:04:38.416394","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. During cardiopulmonary bypass, excessive fibrinolysis occurs due to surgical trauma and blood contact with bypass circuits. By reducing fibrinolysis, tranexamic acid decreases postoperative bleeding and the need for blood transfusions in cardiac surgery patients.","oneSentence":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss during and after cardiopulmonary bypass surgery.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:09.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass surgery"}]},"_fixedFields":["pubmed(76)"],"trialDetails":[{"nctId":"NCT06425614","phase":"NA","title":"COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2024-07-15","conditions":"On-pump Cardiac Surgery, High Risk for Bleeding, Autotransfusion","enrollment":570},{"nctId":"NCT06128330","phase":"PHASE4","title":"Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-15","conditions":"Antifibrinolytic Agents","enrollment":322},{"nctId":"NCT07005661","phase":"PHASE2, PHASE3","title":"Use of PRP in Open Surgery for Type A Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-06-30","conditions":"Aortic Dissection Type A, Transfusions, Platelet Rich Plasma (PRP)","enrollment":250},{"nctId":"NCT06622564","phase":"PHASE3","title":"Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-01-01","conditions":"Bleeding, Surgical Blood Loss, Seizures","enrollment":40},{"nctId":"NCT05966012","phase":"","title":"Tranexamic Acid Dose and Confusion After Cardiac Surgery","status":"UNKNOWN","sponsor":"Papworth Hospital NHS Foundation Trust","startDate":"2023-02-01","conditions":"Cardiovascular Surgery","enrollment":5000},{"nctId":"NCT01914211","phase":"","title":"The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates","status":"WITHDRAWN","sponsor":"Aymen N Naguib","startDate":"2013-07","conditions":"Congenital Heart Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"recentPublications":[{"date":"2025 Nov 25","pmid":"41290755","title":"Changes in blood concentration of tranexamic acid in dialysis and non-dialysis patients undergoing cardiac surgery: a prospective observational cohort study.","journal":"Scientific reports"},{"date":"2025 Nov 7","pmid":"41204089","title":"Effectiveness and safety of low-dose intraoperative tranexamic acid in cardiac surgery: a retrospective before-and-after study.","journal":"BMC anesthesiology"},{"date":"2025 May 1","pmid":"39895347","title":"Fibrinolytic activity in infants undergoing cardiac surgery on cardiopulmonary bypass with routine tranexamic acid: A prospective cohort substudy within the FIBrinogen CONcentrate randomised control trial.","journal":"European journal of anaesthesiology"},{"date":"2024 Sep 27","pmid":"39334224","title":"A multi-center, double-blind, placebo-controlled, randomized, parallel-group, non-inferiority study to compare the efficacy of goal-directed tranexamic acid administration based on viscoelastic test versus preemptive tranexamic acid administration on postoperative bleeding in cardiovascular surgery (GDT trial).","journal":"Trials"},{"date":"2025 Jun","pmid":"38980325","title":"Effects of Fibrinogen Concentrate Supplementation on Postoperative Bleeding in Infants Undergoing Complex Cardiac Surgery.","journal":"Pediatric cardiology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyklokapron"],"phase":"phase_3","status":"active","brandName":"After CPB Tranexamic Acid","genericName":"After CPB Tranexamic Acid","companyName":"Hamilton Health Sciences Corporation","companyId":"hamilton-health-sciences-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss during and after cardiopulmonary bypass surgery. Used for Reduction of blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}